A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
University of Southern California
Novartis
M.D. Anderson Cancer Center
Toray Industries, Inc
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc